FREE Shipping on all US Orders
Alopecia areata is not androgenetic hair loss. The distinction matters — because the treatment is completely different.
Alopecia areata is not androgenetic hair loss. It is an autoimmune condition in which the immune system attacks the hair follicle. Three JAK inhibitors are now FDA-approved for it — with nearly 91% of patients on baricitinib maintaining significant regrowth at 2 years. Understanding whether your hair loss is AGA or AA determines whether any of the treatments covered in this series are relevant to you — or whether a completely different approach applies.
Alopecia areata and androgenetic alopecia can coexist — and frequently do. But their mechanisms are opposite. AGA is driven by DHT and hormonal susceptibility. AA is driven by T-cell immune attack on the follicle. The same product that supports one may be irrelevant to the other. Distinguishing them is the first clinical step.
This series has covered androgenetic alopecia in depth — DHT, estrogen, cortisol, ferritin, thyroid, microbiome, PIILIF, collagen, Gas6, HIF-1α, the pharmaceutical pipeline. Every mechanism we have discussed assumes a specific biological framework: hair loss driven by hormonal susceptibility, progressive follicle miniaturisation, and the multi-driver cascade that botanical and pharmaceutical treatments can address through complementary pathways.
That framework applies to AGA. It does not apply to alopecia areata.
Alopecia areata is an autoimmune condition — the immune system identifies the hair follicle as a target and attacks it. The mechanism is not hormonal. The triggers include genetic predisposition and immune dysregulation. The presentation is different, the diagnosis is different, and the treatment is completely different. Understanding whether your hair loss is AGA, AA, or both simultaneously determines whether everything covered in this series is relevant to your situation — or whether a different clinical path applies entirely.
What AA Actually Is
The autoimmune mechanism — and why it is not what most people assume.
Alopecia areata occurs when T-lymphocytes — the immune cells that normally protect against pathogens — breach the immune privilege of the hair follicle and attack the follicle bulb directly. The hair follicle is normally an "immune-privileged" site — it suppresses local immune activity to protect itself from immune attack during the hair growth cycle. In AA, that privilege collapses. The immune system treats the follicle as foreign tissue and destroys its ability to produce hair.
The follicle itself is not damaged beyond recovery in most cases. The follicle is intact, the bulge stem cells are present, the dermal papilla persists. The hair stops growing because the immune attack disrupts the signalling environment the follicle needs to function — not because the follicle has been permanently destroyed. This is why treatment that restores immune privilege or suppresses the T-cell attack can produce dramatic hair regrowth even in cases of complete scalp loss.
Pattern: AGA produces diffuse thinning or defined receding patterns (frontal, crown). AA typically produces patchy, sharply defined circular or oval areas of complete hair loss — often described as "coin-shaped." The boundary between affected and unaffected areas is usually clear.
Eyebrows and eyelashes: AGA does not affect eyebrows (except the outer third in thyroid involvement). AA can affect eyebrows, eyelashes, beard, and body hair — in severe cases (alopecia totalis, alopecia universalis) producing complete hair loss across the entire body.
Exclamation mark hairs: A hallmark dermoscopy finding in AA — short, broken hairs that are narrower at the base than the tip, resembling exclamation marks. These are found at the margins of the patch and are diagnostic.
Nail changes: Pitting, ridging, or rough texture in the nails occurs in approximately 10–66% of AA patients — a systemic immune involvement not seen in AGA.
The JAK Inhibitor Revolution
What the new treatments do — and what they require.
The treatment paradigm for severe alopecia areata has fundamentally shifted. Three FDA-approved JAK inhibitors now offer 23–40% response rates, far exceeding historical steroid outcomes. JAK inhibitors work by targeting and inhibiting JAK enzymes, which play a significant and diverse role in the immune system — specifically, they block the JAK-STAT signalling pathway through which the cytokines driving follicle immune attack are produced.
The first systemic treatment approved specifically for severe AA. Long-term data confirms sustained efficacy — nearly 91% of patients receiving baricitinib 4mg maintained SALT ≤20 after 104 weeks, with 81.4% achieving SALT ≤10, demonstrating that clinical benefits extend well beyond the first year. Patients who did not achieve the primary endpoint at week 52 but remained on treatment continued to show significant improvement.
The caveat: baricitinib requires continuous use — the JAK-STAT pathway resumes when the drug is stopped, and hair loss typically returns. Using JAK inhibitors over the long term can also change how the medication is distributed, especially for women trying to get pregnant who cannot take JAK inhibitors at that time.
The first treatment approved for adolescents with AA — a significant development given that AA frequently presents in childhood and adolescence. Ritlecitinib's mechanism includes additional effects on TEC kinases, affecting NK cell and cytotoxic T cell activity beyond the primary JAK inhibition. For patients who initially fail to respond to ritlecitinib, switching to brepocitinib provided additional benefit in approximately 25% of cases.
The most recently approved JAK inhibitor for AA — unique in requiring genetic testing before use, which reflects the increasing precision of pharmacogenomic prescribing in dermatology. Genetic variants affect how individuals metabolise the drug, making pre-treatment testing clinically important for efficacy and safety optimisation.
AGA vs AA — The Clinical Comparison
What distinguishes them — and what to do when both are present.
The honest distinction — and why it matters for everything in this series.
Everything covered in this series — Gas6, DHT, cortisol, ferritin, PIILIF, collagen, HIF-1α, the botanical ritual — addresses the AGA mechanism. If your hair loss is primarily driven by the autoimmune attack of alopecia areata, the DHT-targeting botanicals are not the primary treatment. The circulatory support, cortisol reduction, and anti-inflammatory environment the ritual creates may provide complementary benefit — reduced cortisol supports immune regulation, anti-inflammatory botanicals reduce the cytokine environment that AA exploits — but the primary treatment is immune suppression through a JAK inhibitor or corticosteroid protocol under medical supervision.
This is not a reason to avoid the ritual. Public interest in JAK inhibitors for alopecia areata increased following media coverage — highlighting the need for patient education and physician guidance on appropriate indications and treatment selection for hair loss disorders. AA and AGA coexist frequently. The botanical ritual addresses AGA; the JAK inhibitor addresses AA. Both can operate simultaneously, through separate mechanisms, in the same person.
The most important step is accurate diagnosis — a dermoscopy examination and biopsy if needed, by a trichologist or dermatologist who can distinguish AA from AGA and identify when both are present. The treatment that works for one is not the treatment that works for the other. Knowing which you have is the first clinical step.
One diagnosis determines everything.
For the AGA component — the botanical ritual.
If your hair loss is androgenetic — or if you have both AGA and AA — the Fertile Roots ritual addresses the AGA drivers while medical treatment addresses the autoimmune component.
→ Explore the Fertile Roots CollectionScience, ritual, and botanical intelligence — delivered daily.
Each morning, one article. New research, ancient wisdom, and the honest science of hair and scalp health. Written for women who want to understand what is happening — not just what to buy.
By subscribing you agree to receive email from Laritelle Organic. Unsubscribe at any time.